SynthesisOrphanet journal of rare diseases2026
Evaluating the relationship between antidrug antibodies and efficacy and safety outcomes in patients with Fabry disease receiving enzyme replacement therapy: a systematic literature review.
Synthesis in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFabry disease is a lysosomal storage disorder caused by deficient activity of the enzyme α-galactosidase A, resulting in progressive accumulation of globotriaosylceramide (Gb3) and widespread tissue and organ damage. Enzyme replacement therapy (ERT) can slow disease progression but may elicit antidrug antibody (ADA) responses. The impact of ADA status on long-term ERT efficacy and safety remains incompletely understood.
objectiveWe conducted a systematic literature review (SLR) to examine the impact of ADA status on outcomes in patients with Fabry disease receiving ERT. We aimed to evaluate associations between ADA status and specific outcomes, and to identify remaining evidence needs.
methodsSystematic searches were conducted in MEDLINE and Embase (up to March 4, 2025), supplemented by searches of the Cochrane Library and clinical trial registries. Eligible publications reported data on the relationship between ADA status and Fabry disease-related biomarkers (Gb3, globotriaosylsphingosine [lyso-Gb3]), efficacy (renal and cardiovascular) outcomes, and safety (adverse events [AEs] and infusion-related reactions [IRRs]) outcomes.
resultsOf 1763 articles screened, 24 were included (19 reported disease-related biomarkers, 10 renal outcomes, 4 cardiovascular, and 9 AE/IRR data). Most analyses of disease-related biomarkers (17/18) reported statistically significant positive associations (p < 0.05) between ADA positivity and elevated biomarkers: plasma lyso-Gb3 (4/8 studies), plasma Gb3 (1/3 studies), and urine Gb3 (6/6 studies). Some renal data sets (2/9) reported evidence suggesting a potential association between more rapid decline in estimated glomerular filtration rate in ADA-positive (vs ADA-negative) patients. Four out of 9 studies reported statistically significant associations between ADA positivity and IRR occurrence; most studies stratifying IRR rates by ADA status (5/7) reported higher rates among ADA-positive (vs ADA-negative) subgroups.
conclusionThis SLR found evidence that ADA positivity may be associated with increased IRR risk and may have a negative effect on some measures of ERT efficacy. Inconsistencies in the identified data were likely driven by study design differences, including prior ERT exposure, follow-up time, and ADA assessment protocols. Additional prospective studies with standardized ADA assessments and accounting for patient baseline characteristics and disease severity, are needed to better understand the clinical implications of ADA formation on ERT outcomes, including an assessment of causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.